Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349995 | 0.78 | BACE1 (0.46) | BACE1KCNN4CYP2D6SLC6A4 | |
| SCHEMBL4194615 | 0.78 | BACE1 (0.40) | BACE1TAAR1KCNN4KIF11CYP2D6 | |
| SCHEMBL5224458 | 0.74 | BACE1 (0.56) | BACE1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL30318970 | 0.70 | BACE1 (0.46) | BACE1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL469181 | 0.70 | KCNN4 (0.64) | TAAR1KCNN4KIF11 | |
| SCHEMBL14511191 | 0.69 | MAPT (0.46) | TAAR1AOC3SLC6A2MAOASLC6A4 | |
| SCHEMBL20357562 | 0.69 | KIF11 (0.64) | TAAR1KCNN4KIF11 | |
| SCHEMBL28483268 | 0.69 | TAAR1 (0.36) | TAAR1KCNN4KIF11AOC3CYP2D6 | |
| Hydrochloric Acid SCHEMBL9957339 | 0.69 | KCNN4 (0.61) | TAAR1KCNN4KIF11CYP2D6 | |
| SCHEMBL13900473 | 0.69 | KCNN4 (0.45) | TAAR1KCNN4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | BACE1 2407/4885TAAR1 92/4885KCNN4 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.